Coherus BioSciences, Inc.Panjang
CHRS - upcoming catalyst - breakout ahead ?
Telah dikemas kini
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
This is not a financial advice!
Upcoming catalyst in 2024
A few block buys last months
Short Float 26.86 %
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Key level is 2.5 - needs to get broken.
Keep an eye on 2.85 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 2.15
TP approx. 3.7
Most info on the chart.
Trade carefully!
This is not a financial advice!
Upcoming catalyst in 2024
A few block buys last months
Short Float 26.86 %
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Key level is 2.5 - needs to get broken.
Keep an eye on 2.85 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 2.15
TP approx. 3.7
Most info on the chart.
Trade carefully!
Dagangan ditutup: hentian tercapai
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.